Introduction
Keratinocyte (basal and squamous cell) skin cancers are the most common types of human malignancy. Since the 1960s, the average rise in new cases has been 3-8% per year (1) . This trend is projected to continue because of depletion of stratospheric ozone, increased exposure to solar radiation, and longer life expectancy.
Indeed, cutaneous squamous cell carcinomas (cSCC) are rapidly increasing in incidence, causing significant morbidity and mortality (2) . In the 10-year period from 2001 to 2011, Scotland has seen a greater than 50% increase in the incidence of cSCC, with now around 3,000 new cases diagnosed annually and associated escalating healthcare burden and cost (3). In the US, there were estimated 400,000 new cases of cSCC diagnosed in 2012 alone (4) . It has been suggested that cSCC represent an under-recognized health issue, and that deaths from cSCC may be as common as deaths from renal and oropharyngeal carcinomas, and melanoma in some parts of the USA (4). This is particularly relevant to patients with multiple cSCC tumors, who have markedly elevated risks of recurrence and metastasis (5) .
cSCC typically arise in areas of "field change" on the head and neck where cumulative ultraviolet radiation (UVR) damage from the sun has induced multiple pre-invasive skin lesions. Indeed, UVR is now well recognized as the major factor in the etiology of skin cancer (6) . Being the most ubiquitous carcinogen in our environment, UVR is a complete carcinogen (an initiator and a promoter). The solar UV spectrum has two physiologically relevant wavelength components, the shorter and more highly energetic UVB (280-315 nm), which damages the epidermis of the skin, and the longer and more penetrant UVA (315-400 nm), which reaches the underlying dermis. Exposure to solar UVR causes generation of reactive oxygen species (ROS), damage to DNA, lipids and proteins, including DNA damage repair proteins, inflammation, and immunosuppression (1) . Together, these deleterious processes contribute to skin photoageing and photocarcinogenesis.
In addition to being among the most common, cSCCs are among the most highly mutated human malignancies, with reported mutation rates of 33-50 per Mb of coding sequence (7, 8) . Such extraordinarily high mutation burden makes the possibility for success of a single-target therapy unlikely and highlights the need for development of prevention strategies. To be able to test candidates and develop strategies for skin cancer prevention (and/or treatment) agents, it is essential to have a 4 preclinical model that closely recapitulates the development of the human disease.
One of the most commonly used skin carcinogenesis models is the mutant HarveyRas (Hras(Q61L))-driven papilloma formation induced by topical treatment with the carcinogen 7,12-dimethylbenz[a]anthracene (DMBA) as the initiator, followed by chronic applications of 12-O-tetradecanoylphorbol-13-acetate (TPA) as the promoter.
Recently, two independent groups have conducted comprehensive analyses of the mutational landscape of the mouse tumors that form in this model, confirming the driver mutations in Ras (Hras, Kras and Rras2) genes with a characteristic DMBA/TPA signature (i.e. A>T and G>T transversions), which occur in a mutuallyexclusive fashion in ~90% of the tumors (9, 10) . Although mutations in other genes were also identified, most of them did not have the DMBA signature, suggesting that they occur at the later stages during tumor development (9) . Whereas the DMBA/TPA model constitutes an excellent model for RAS-driven tumors, as demonstrated by the significantly overlapping genes between the mouse tumors that form in this model and human SCC from cervix (44%), head and neck (35%), esophagus (25%) and lung (18%) (9), activating mutations in RAS genes are infrequent (<11%) in human cSCC (8) . In contrast to human cSCC, the DMBA/TPA-induced mouse tumors carry an average of 5.2 mutations per Mb of coding sequence (10) . Overall, tumors that arise in this model do not represent the extraordinarily high level and broad spectrum of mutations that are characteristic of human cSCC.
A second skin carcinogenesis model uses UVB as the carcinogen. However, this model does not reflect sun exposure accurately as the solar UVR that reaches the surface of the earth consists predominantly (~95%) of UVA, with only a small (albeit more carcinogenic) component of UVB wavelengths. The presence of the UVA component is particularly relevant for modelling the development of cSCC in specific high-risk populations, including patients that are undergoing chronic life-long treatment with thiopurine immunosuppressive and anti-inflammatory drugs, such as solid organ transplants recipients and inflammatory bowel disease patients. This is because the combination of UVA and the thiopurine metabolites that incorporate into DNA of proliferating skin cells is highly mutagenic, causing damage to DNA and DNA damage repair proteins (11) (12) (13) . Indeed, azathioprine treatment photosensitizes the human skin to UVA radiation (14) , and the skin cancer risk in organ transplant recipients is ~100-fold greater compared to the general population (15) .
To overcome these limitations and build upon the "high-risk" skin carcinogenesis model in SKH-1 hairless mice (16, 17) , we have developed a model in which immunocompetent SKH-1 hairless mice are subjected chronically and intermittently to sub-erythemal doses of solar-simulated UVR twice a week for 15 weeks (18) . Irradiation is then discontinued, and tumor development is monitored.
Although there are no tumor-bearing mice at the end of the period of irradiation, essentially all animals develop tumors during the subsequent 15-20 weeks, in the absence of further exposure to UVR. By use of this model, we found that genetic or pharmacologic upregulation of transcription factor NF-E2 p45-related factor 2 (Nrf2) protects against tumor development (18, 19) . Importantly, protection was observed in Together, these findings imply that the "high-risk" solar-simulated UVR skin carcinogenesis mouse model represents a valid model for human cSCC, and justify its use for preclinical testing during the drug development process of topical and/or systemic agents for the prevention and treatment of human cSCC. Furthermore, such testing could be performed on cancer preventive agents, which have UVR-absorbing effects (e.g. sunscreens) and are applied during the irradiation period, as well as on drug candidates, which act by non-UVR-filtering mechanisms and are applied during the tumor development period after cessation of the UV irradiation schedule.
Materials and Methods

Animals
The animal experiments were performed according to the rules and regulations described in the UK Animals (Scientific Procedures) Act 1986. All experimental animals were age-matched and female. The animal study plan was developed after 6 ethical approval was granted (Project Licence 60/5986), and was further approved by the Named Veterinary Surgeon and the Director of Biological Services of the University of Dundee. SKH-1 hairless mice (initially obtained form Charles River, Germany) were bred and maintained in the Medical School Resource Unit of the University of Dundee on a 12-h light/ 12-h dark cycle and 35% humidity. Throughout the study, the animals had free access to water and pelleted RM1 diet (SDS Ltd., Witham, Essex, UK).
Cutaneous carcinogenesis
Cutaneous carcinogenesis was initiated when the mice were 8-weeks old by subjecting the animals chronically twice a week (on Tuesdays and Fridays) for 15 weeks to solar-simulated UVR (comprised of 2 J/cm 2 UVA and 90 mJ/cm 2 UVB).
UVA340 lamps (Q-Lab, Germany) were used as the irradiation source. Irradiation from these lamps simulates the solar UVR from 365 nm to the solar cut-off of 295 nm, with a peak emission at 340 nm. The radiant dose was quantified with a UVB Daavlin Flex Control Integrating Dosimeter, and was further confirmed by use of an external radiometer (X-96 Irradiance Meter; Daavlin, Bryan, OH) before and after each irradiation session. The mice were placed in clear, bedding-free cages and then exposed to UVR. To prevent excessive heating and discomfort to the animals, the irradiation unit (Daavlin, Bryan, OH) was equipped with an electrical fan. Tumors (defined as lesions >1 mm in diameter) that formed on the dorsal skin were measured and mapped once a week.
Sample preparation for whole exome sequencing
The experiment was terminated and the tumors were collected at 20 weeks after completion of the irradiation schedule (i.e., 35 weeks after the onset of irradiation). The tumor samples were snap-frozen in liquid N 2 , and stored at -80°C.
Normal non-irradiated ventral skin from the same animals was also obtained at the 
Data analysis
Raw sequencing reads were aligned to the reference genome (UCSC mm9) using Bowtie2, a fast sensitive read alignment software (21) . Single Nucleotide
Variants (SNV) that differed between tumor and normal samples were identified using SomaticSniper 1.0.5. with somatic score filter set at 40 (22) . Small insertions and deletions (INDELs) were called using Platypus, a haplotype-based variant caller for next generation sequencing (23) . Mutation calls were annotated using SNPEff (24) .
Copy number alterations were estimated from the exome sequencing data using the cn.MOPS (Copy Number estimation by a Mixture Of PoissonS') algorithm (25) .
Matched normal samples processed in the same batch as the tumor samples were used as controls to identify sample specific copy number alterations. The mapped reads for the exome sequencing have been deposited in the Sequence Read Archive (SRA) database (Project Number: PRJNA352449). Mutational signature and statistical analyses were performed in R statistical environment (26) .
Results and Discussion
Mouse cutaneous SCC induced by chronic exposure to solar-simulated UVR share similar histopathology with human cutaneous SCC
The development of cSCC in humans is usually associated with chronic sun exposure in early life (27) . We therefore subjected mice, beginning at 8 weeks of age, (18, 19) . Interestingly, many animals displayed a "field change", also known as "field cancerization" (28) , which is a typical representation of the clinical situation.
This observation implies that, similar to humans, SKH-1 hairless mice develop multiple primary cSCC in close proximity arising within histologically dysplastic epithelium following chronic intermittent exposure to solar-simulated UVR.
The histopathological spectrum of the mouse cutaneous squamous cell carcinomas (mcSCC) that develop in this model resembles very closely the spectrum of human cutaneous squamous cell carcinomas (hcSCC) (Figure 2 and Table 1 
Somatic point mutations manifest prominent UV signature
We performed exome sequencing of 18 microdissected tumor samples (cases)
derived from our SKH-1 hairless mice that had been chronically exposed to solarsimulated UVR as described in Materials and Methods. Tumor selection was based on size. The size and histopathological characteristics of each individual tumor are described in detail in Table 1 Table 2 ).
Our results show a remarkably similar mutational signature of the mcSCC to the mutational signature previously described in hcSCC (8, 33) . Pickering and colleagues reported that an average of 75% of the mutational events in human patient cases were C>T transitions, and that 85% of these mutations were found at locations following a pyrimidine base (33) . Similarly, South and colleagues observed that ~68% of all SNP mutations were C>T transitions in an independent cohort of hcSCC samples (8) . Critically, direct comparison of these previously analyzed human hcSCC cases and our mcSCC tumors showed high overlap in terms of both frequency and type of SNP mutations uncovered ( Figure 3D ). Figure 1) . Moreover, similar comparison also revealed high correlation in terms of mutation signature between the mcSCC and a UVR associated melanoma mouse model ( Figure 3F, Supplementary Figure 1 ).
Copy-number alteration
Pickering and co-workers reported recurring regions of copy number gain on chromosomes 7, 8q, 9q, 14, and 20. To compare the mcSCC to the reported copy number alteration in hcSCC, we estimated copy number alteration from our exome sequencing data. Recurring (in at least 3 of the 18 tumor samples) regions of copy number gains were detected on chromosome 2, 5, 7, 12, 14, 15, and 18 ( Table 2,   Supplementary Table 3) . Interestingly, genes located within these regions significantly overlapped with those located in the regions of gains (chromosomes 14, 7, and 8q) reported in hcSCC ( or NOTCH2 loss-of-function mutations being present in ~75% of hcSCCs (35) . We therefore conducted a detailed analysis on the mutations in Trp53 and Notch genes that were detected in our mcSCC tumor samples.
A total of 21 independent non-synonymous mutations were found in the Trp53 As noted above, loss-of-function mutation in NOTCH1 or NOTCH2 occur in ~75% of hcSCC (35) , and are considered to be an early event in the development of 
Conclusion
Taken together, data presented in this study show that the skin tumors that develop in this mouse model are similar to human cSCC tumors in terms of histopathology, mutational characteristics, and UVR-induced mutational signature.
We conclude that by: (i) using UVR as the carcinogen, (ii) incorporating both the UVA and the UVB components of the solar UVR at their natural ratio, and (iii) employing chronic but intermittent irradiation schedule, this mouse skin carcinogenesis model has high relevance to the human disease. We propose the use of the model for mechanistic studies aiming to further our understanding of cSCC development, as well as for testing potential prevention and treatment strategies for human cSCC.
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